PRESS RELEASE published on 08/14/2026 at 10:27, 1 month 6 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Innate Pharma prices €30 million offering of Ordinary Shares at €1.70 per share in Marseille, France. Proceeds will fund clinical development and ADC portfolio advancement Ordinary Shares Clinical Development Offering Innate Pharma ADC Portfolio
BRIEF published on 08/13/2026 at 22:05, 1 month 7 days ago Innate Pharma Launches €22.5 Million Share Offering Euronext Paris Clinical Development Share Offering Innate Pharma Institutional Buyers
PRESS RELEASE published on 08/13/2026 at 22:00, 1 month 7 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Innate Pharma announces proposed offering of ordinary shares worth approximately t €22.5 million, anchored by global coordinator Stifel, for continued clinical development and corporate purposes Ordinary Shares Clinical Development Offering Innate Pharma Stifel
BRIEF published on 08/10/2026 at 08:35, 1 month 10 days ago Innate Pharma Advances Lacutamab into Phase 3 Trial with Sobi Innate Pharma Lacutamab Phase 3 TELLOMAK-3 Markus Jensen Sobi Partnership
BRIEF published on 05/19/2026 at 07:05, 4 months 1 day ago Innate Pharma at the Jefferies Global Healthcare Conference Immunotherapy Cancer Innate Pharma Therapeutic Antibodies Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 4 months 1 day ago Innate Pharma to Attend Jefferies Global Healthcare Conference Biotechnology Cancer Treatment Immunotherapy Innate Pharma Jefferies Conference
PRESS RELEASE published on 05/19/2026 at 07:00, 4 months 1 day ago Inside Information / Other news releases Innate Pharma to participate in Jefferies Global Healthcare Conference on June 2-4, 2026 in New York, United States. Developing immunotherapies for cancer patients Biotechnology Innate Pharma Jefferies Global Healthcare Conference Immunothérapies Cancer Patients
BRIEF published on 04/17/2026 at 21:05, 5 months 3 days ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 5 months 3 days ago Innate Pharma presents interim results from the MATISSE trial at the AACR congress Lung Cancer Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
PRESS RELEASE published on 04/17/2026 at 21:00, 5 months 3 days ago Inside Information / Other news releases Innate Pharma to present interim results of IPH5201 in MATISSE Phase 2 study at AACR 2026. Study aims to enhance NSCLC treatment with anti-CD39 monoclonal antibody NSCLC Innate Pharma AACR 2026 MATISSE Phase 2 IPH5201
Published on 09/19/2026 at 00:55, 1 day 21 hours ago Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 22:00, 2 days ago Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 2 days 2 hours ago Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 2 days 8 hours ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/20/2026 at 15:10, 7 hours 33 minutes ago MSITEK Participates in New York Fashion Week Retail Innovation Lab
Published on 09/20/2026 at 09:05, 13 hours 38 minutes ago Huawei Digital Power Showcases Multi-Scenario Solutions Featuring Grid Forming and AI at IDEE 2026
Published on 09/20/2026 at 06:30, 16 hours 13 minutes ago Huawei Grid-Interactive AIDC Solution: Shaping the New Paradigm of AI Infrastructure
Published on 09/20/2026 at 04:35, 18 hours 8 minutes ago How to Achieve Sustainable Power Without Changing Your Existing Backup System
Published on 09/19/2026 at 16:40, 1 day 6 hours ago 2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens
Published on 09/18/2026 at 18:34, 2 days 4 hours ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/17/2026 at 17:40, 3 days 5 hours ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
